Icon inks Proteome deal to bolster biomarker offering

By Nick TAYLOR contact

- Last updated on GMT

Related tags: Protein

Icon is adding protein and peptide profiling to its biomarker capabilities through a strategic alliance with Proteome Sciences.

Over the past 10 years Icon has built up its biomarker capabilities as it works to help clients make more informed drug development decisions. Building on this progress Icon has inked a deal with Proteome.

At AAPS 2010 Outsourcing-Pharma discussed the deal with Brian O'Dwyer, vice president (VP) of bioanalytical development, and John Allinson, VP biomarker lab services.

In a press statement Ian Pike, chief operating officer at Proteome, said the deal is recognition of the ‘unique power’ of its proprietary technology platforms.

Related news

Show more

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars